Multiple Sclerosis | Emerging Therapies | Ocrevus Relapsing Forms of Multiple Sclerosis - Wave 3 (US)

Publish date: July 2018

Login to access report

Market Overview

Ocrevus is the latest disease-modifying therapy (DMT) to launch for the treatment of relapsing forms of multiple sclerosis (MS) in the United States, and easily one of the most significant. Its novel mechanism offers potent efficacy and yields a safety profile that may set it apart from other highly efficacious—but risk-prone—DMTs. A competitive price offering from Genentech/Roche coupled with a clean, unrestrictive label will ease neurologists’ incorporation of Ocrevus into practice. DRG’s launch-tracking series will examine how the perception and performance of Ocrevus evolves through Year One in an MS market still waiting for the DMT that balances efficacy and risk better than Tysabri or Tecfidera, and a field that perennially debates the merits of early, aggressive intervention.

Questions Answered

  • What is the awareness of, familiarity with, and perceptions related to Ocrevus among U.S. neurologists?
  • For which relapsing MS patients are neurologists prescribing Ocrevus, what are the reasons for prescribing in relapsing MS, and how satisfied are they with Ocrevus?
  • What promotional messages and activities are Genentech/Roche employing in support of the Ocrevus launch in relapsing MS?
  • How does the trial and adoption of Ocrevus compare to other recent product launches in the relapsing MS market? How do adopters and nonadopters of Ocrevus in the largest MS subpopulation compare across key metrics?

Product Description

Emerging Therapies: is a three-wave series based on primary research data collected at 1, 6, and 12 months postcommercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.

Markets covered: United States

Primary research: Survey of approximately 75 U.S. neurologists

Key metrics included:

  • Unaided and aided awareness of Ocrevus.
  • Familiarity with and impressions of Ocrevus.
  • Prescriber and nonprescriber profiles.
  • Willingness to prescribe Ocrevus.
  • Performance of Ocrevus on key attributes.
  • Sales representative frequency, reach, and satisfaction.
  • Benchmarking against previously launched multiple sclerosis agents.

Table of contents

  • Ocrevus Relapsing Forms of Multiple Sclerosis - Wave 3 (US)
    • Key Findings
    • Benchmarking Ocrevus's Launch Success vs. Other Launched Drugs
      • Ocrevus Has Outperformed Most Benchmark DMTs After One Year
    • Prescriber and Nonprescriber Profiles
      • Differences Between Ocrevus Prescribers and Nonprescribers for Relapsing Forms of MS
    • Ocrevus Awareness and Perceptions
      • Unaided and Aided Awareness of Ocrevus
        • Ocrevus Is a Top-of-Mind DMT for Surveyed Neurologists at Twelve Months Postlaunch, and Awareness of Its Characteristics Is High
      • Familiarity with Ocrevus
        • Neurologists' Familiarity with Ocrevus Improved Steadily Across Waves Through Year One
      • Sources of Familiarity with Ocrevus
        • During Ocrevus's First Year, Neurologists' Sources of Familiarity Have Shifted Toward Marketing Contact
      • Initial Reaction to and Interest in Ocrevus
        • Neurologist Reaction to and Interest in Ocrevus Remains Strong After Twelve Months on the Market
      • Impressions of Ocrevus
        • Neurologists Cite Efficacy and Dosing Frequency as Ocrevus's Key Advantages
      • Prescriber and Nonprescriber Profiles
        • Ocrevus Nonprescribers at One Year Postlaunch Have Smaller Practices, Use Older DMTs, and Are More Risk-Averse Than Prescribers
    • Ocrevus Trial and Use
      • Willingness to Prescribe Ocrevus
        • Surveyed Neurologists Have Been Highly Willing to Prescribe Ocrevus Since Its Launch
      • Number of Patients Currently Receiving Ocrevus
        • The Majority of Ocrevus-Treated Relapsing MS Patients at One Year Postlaunch Were Switched from a Previous DMT
      • Reasons for Not Yet Prescribing Ocrevus
        • At Twelve Months Postlaunch, Safety and Market Access Concerns Among Ocrevus Nonprescribers Linger
      • Anticipated Ocrevus Use
        • Surveyed Neurologists at Twelve Months Postlaunch Anticipate Robust Growth in Their Prescribing of Ocrevus for Relapsing Forms of MS
      • Ocrevus Performance on Key Attributes
        • More Surveyed Neurologists at Twelve Months Postlaunch Are Likely to Prescribe Ocrevus Before Lemtrada, Tysabri, and Gilenya
    • Effectiveness of Face-to-Face Detailing for Ocrevus
      • Ocrevus Sales Representative Frequency and Reach
        • Recent Sales Representative Contact Has Remained Low Over Ocrevus's First Year on the Market
      • Satisfaction with Ocrevus Sales Representative
        • Satisfaction with Ocrevus Sales Representative Contact Remains High at Twelve Months Postlaunch
      • Ocrevus Message Recall
        • Ocrevus's Indication for PP-MS Is a Key Topic for Messaging by Sales Representatives at Twelve Months Postlaunch
    • Methodology
      • Primary Market Research Methodology
    • Appendix
      • Primary Market Research

Author(s): Natalie Taylor, PhD; Jonathan Searles

Natalie Taylor, is a Principal Business Insights Analyst with the central nervous system/ophthalmology disorders team at Decision Resources Group. She has over ten years of experience authoring primary and market research reports for pharmaceutical industry clients across multiple psychiatry, pain, neurology, and ophthalmology therapy areas. Prior to joining DRG, Dr. Taylor worked at QuintilesIMS as manager of the central nervous system portfolio of Disease Insights market forecasting offerings. She completed her in Physiology at Dartmouth College in Hanover, New Hampshire, where she studied the role of serotonergic neurons in the medullary raphe on modulating respiratory responses in mammals. She holds a in Biology from Dickinson College in Carlisle, Pennsylvania.

Jonathan ;Searles is a Senior Director in the CNS/Ophthalmology unit at DRG, overseeing the neurology research stream. Prior to joining DRG, ;Searles received a degree, summa cum laude, from Brandeis University; during this time, Mr. Searles conducted research projects at the Harvard University Peabody Museum and at Brandeis.